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We present a case of adult Pompe disease (acid maltase deﬁciency) with an uncommon clinical presentation characterized by severe
fatigue and myalgia prior to the onset of limb girdle weakness. Remarkably, the muscle biopsy demonstrated selective involvement of
type 1 muscle ﬁbers. The cause and clinical eﬀects of ﬁber type speciﬁc involvement are currently unknown, but the phenomenon might
contribute to the clinical heterogeneity in Pompe disease and the variable response to enzyme replacement therapy.
 2010 Elsevier B.V.
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Limb-girdle weakness is the most common and promi-
nent presenting sign in adults with Pompe disease, an auto-
somal recessive metabolic disorder often referred to as acid
maltase deﬁciency or glycogen storage disease type II
(OMIM #232300). Pompe disease is a lysosomal storage
disorder caused by the deﬁciency of acid a-glucosidase
[1–4]. Expansion and malfunction of the lysosomal system
followed by autophagosomal build-up leads to loss of mus-
cle architecture and muscle function [5–9].
The clinical spectrum of Pompe disease is very heteroge-
neous with regard to the age of onset, disease manifestations0960-8966  2010 Elsevier B.V.
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examination of skeletal muscle from Pompe disease patients
usually reveals a vacuolar myopathy and glycogen storage
with nonselective involvement of the diﬀerent muscle ﬁber
types [4]. However, a limited number of cases have been
reported showing preferential involvement of either type 1
[11–13] or type 2muscle ﬁbers [14]. In all seven cases reported,
the selective ﬁber type involvement was just reported as an
unusual observation and it was not questioned whether
patientswith preferential glycogen storage inone speciﬁc ﬁber
type might exhibit a diﬀerent clinical phenotype.
We present a case of adult-onset Pompe disease with an
uncommon clinical presentation characterized by severe
fatigue and myalgia prior to the onset of limb girdle weak-
ness. Remarkably, the muscle biopsy demonstrated involve-
ment of only type 1muscle ﬁbers. This unusual observation is
relevant in the context of recent publications suggesting that
type 1 muscle ﬁbers might respond better to enzyme replace-
ment therapy than type 2 ﬁbers [15–17].
Fig. 1. Biopsy from the m. quadriceps femoralis showing selective
involvement of type I muscle ﬁbers. ATPase staining at pH 9.4: Type 1
muscle ﬁbers are lightly stained and are vacuolated (panel A). Acid
phosphatase staining (red) of a serial section demonstrates lysosomal
pathology in the type I muscle ﬁbers (panel B).
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In January 2007, a 35-year-old Caucasian woman was
referred to our hospital. Since August 2006 she suﬀered
from severe fatigue and myalgia of the muscles of the
shoulder girdle and the upper arms and limbs, especially
notable when she walked the stairs and combed her hair.
A few months later, she had noted minor weakness of the
upper arms and legs. Because of these complaints she had
abandoned her job as a children day-care worker. There
were no clinical signs, such as feeling listless, being without
energy, or a lack of motivation, suggesting a vital depres-
sion. Physical examination revealed no abnormalities. Neu-
rological examination revealed no muscular atrophy or
fasciculations. The muscles were not abnormally tender.
Examination of the cranial nerves, sensory functions of
the limbs and tendon reﬂexes were normal. There was sym-
metrical weakness of the shoulder girdle (m. deltoideus, m.
infraspinatus), the gluteal muscles and the proximal mus-
cles of the legs (m. iliopsoas, hamstrings), Medical
Research Council (MRC) grade 4. The patient was able
to squat, but used her hands to rise from the ﬂoor. Pulmon-
ary function tests were normal. She had a mean score of
6.75 (range 0–7) on the fatigue severity scale (FSS), indicat-
ing severe fatigue.
Serum creatine kinase (CK) was elevated (1755 U/l; nor-
mal value <169 U/l). Aspartate aminotransferase (AST),
alanine aminotransferase (ALT) and lactate dehydrogenase
(LDH) were slightly elevated. Erythrocyte sedimentation
rate (ESR) and thyroid-stimulating hormone (TSH) were
normal. Antinuclear antibodies (ANA), anti-SSA, anti-
SSB and anti-Jo1, were negative (normal).
Based on the relatively short duration of her complaints,
the presence of fatigue, myalgia, and the elevated CK, we
considered it most likely that she would have an inﬂamma-
tory myopathy. A muscle biopsy taken from the quadriceps
muscle, however, revealed no signs of inﬂammation, but
rather surprisingly showed a vacuolar myopathy solely
aﬀecting type 1 muscle ﬁbers. The vacuoles stained positive
for acid phosphatase. Representative pictures are shown in
Fig. 1. Glycogen accumulation in some muscle ﬁbers was
detected by PAS staining and electron microscopy showed
glycogen-ﬁlled vacuoles. No abnormalities were found in
the NADH (nicotinamide adenine dinucleotide), SDH
(succinate dehydrogenase), COX (cytochrome oxidase)
and ORO (oil red O) staining. Based on these ﬁndings
Pompe disease was suspected and subsequently conﬁrmed
by demonstrating acid a-glucosidase deﬁciency in leuco-
cytes and cultured skin ﬁbroblasts. In addition, DNA anal-
ysis revealed the presence of two pathogenic mutations in
the acid a-glucosidase gene, c.-32-13 T > G and 525delT.
3. Discussion
The case of Pompe disease described here is peculiar in
that the patient presented with severe fatigue and myalgia
prior to the development of limb-girdle weakness, andbecause ﬁber type involvement was restricted to the type
1 muscle ﬁbers. Whether rapid progression, fatigue or pain
is related to oxidative type 1 muscle ﬁber abnormalities in
this patient is uncertain and has not been proven.
Although fatigue is prevalent in adults with Pompe dis-
ease, it is rarely reported as ﬁrst symptom [18]. Fatigue can
have many diﬀerent causes [19]. In case of Pompe disease,
expansion and dysfunction of the lysosomal system due to
glycogen accumulation followed and accompanied by
autophagic build-up destroys the muscle architecture and
hampers the contraction [20]. Thus, it takes more energy
to achieve the same power of contraction resulting in more
rapid fatigue [19,21]. Decreased pulmonary function may
also contribute to the level of fatigue, but our patient
had a normal pulmonary function in both sitting and
supine position. Muscle ﬁber type distribution varies
widely within and between muscles depending on their
function [22]. Therefore the selective involvement of type
1 muscle ﬁbers in this case can be a chance ﬁnding and the-
oretically can be related to sampling diﬀerences, but might
be related to the prominent fatigue, rapid progression or
pain. Normally, type 1 muscle ﬁbers are fatigue-resistant
and well suited for prolonged aerobic exercise [22]. If type
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muscle ﬁbers might be challenged to partially compensate
for the loss of function while they are not suited for endur-
ance. Whether these mechanisms explain the fatigue in our
patient is as yet unknown. Perception of fatigue may also
be related to non-physical causes [23].
Selective type 1 muscle ﬁber involvement with vacuoliza-
tion has previously been described in a limited number of
cases of Pompe disease, but no discussion was devoted to
its cause or clinical eﬀects. Three of these ﬁve patients suf-
fered from respiratory dysfunction, which is likely to cause
fatigue, but pulmonary dysfunction was not found in the
case we present. The muscle ﬁber type speciﬁc involvement
however could be relevant in clinical practice because it
could have an impact on the eﬀect of enzyme replacement
therapy.
Research in mice showed that slow-twitch type 1 ﬁbers
respond well to ERT in contrast to type 2 ﬁbers. In partic-
ular, type 2b ﬁbers seemed much more resistant to therapy.
In knockout mice it was shown that the accumulation of
autophagic vacuoles in skeletal muscle is limited to type 2
ﬁbers. The combination of increased autophagic activity
and ineﬃcient endocytic traﬃcking in type 2 ﬁbers may
contribute to an incomplete therapeutic response [15,24].
However in a single patient with classic infantile Pompe
disease it was shown that enzyme replacement therapy
can reverse the pathological changes in both type 1 and
type 2a muscle ﬁbers [17].
With this case report we want to draw attention to the
occurrence of ﬁber type speciﬁc pathology in Pompe dis-
ease. It may be relevant for the clinical presentation and
for the responsiveness to enzyme therapy, since it has been
suggested, that type 1 ﬁbers respond better to enzyme ther-
apy than type 2 ﬁbers [17,24]. Further research is required
in adults with Pompe disease to draw further conclusions
about the eﬀect of ﬁber type speciﬁc involvement.
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